Stock Track | HUTCHMED Soars as UK Approves Cancer Drug Fruquintinib

Stock Track

2024-09-20

Shares of HUTCHMED (HCM), a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.

The Medicines and Healthcare products Regulatory Agency (MHRA) approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.

The regulatory greenlight bolsters HUTCHMED's oncology portfolio and is expected to drive revenue growth for the company. Analysts view the approval as a positive development, highlighting the drug's potential in addressing a significant unmet medical need in the treatment of metastatic colorectal cancer.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1151558670"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151558670\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1151558670?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-20 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151558670","market":"hk","top_or_hot":-1,"title":"Stock Track | HUTCHMED Soars as UK Approves Cancer Drug Fruquintinib","media":"Stock Track","content":"<html><body><p>Shares of HUTCHMED (HCM), a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.</p>\n<p>The Medicines and Healthcare products Regulatory Agency (MHRA) approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.</p>\n<p>The regulatory greenlight bolsters HUTCHMED's oncology portfolio and is expected to drive revenue growth for the company. Analysts view the approval as a positive development, highlighting the drug's potential in addressing a significant unmet medical need in the treatment of metastatic colorectal cancer.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | HUTCHMED Soars as UK Approves Cancer Drug Fruquintinib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HUTCHMED Soars as UK Approves Cancer Drug Fruquintinib\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-09-20 20:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of HUTCHMED (HCM), a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.</p>\n<p>The Medicines and Healthcare products Regulatory Agency (MHRA) approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.</p>\n<p>The regulatory greenlight bolsters HUTCHMED's oncology portfolio and is expected to drive revenue growth for the company. Analysts view the approval as a positive development, highlighting the drug's potential in addressing a significant unmet medical need in the treatment of metastatic colorectal cancer.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黃醫藥","start_time":0,"source_url":"","article_id":"1151558670","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151558670","pubTimestamp":1726835540,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of HUTCHMED , a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.The Medicines and Healthcare products Regulatory Agency  approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and poten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00013":"和黄医药"},"translate_title":"英国批准抗癌药物呋喹替尼，和黄医药股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1},"content_text":"Shares of HUTCHMED (HCM), a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.\nThe Medicines and Healthcare products Regulatory Agency (MHRA) approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.\nThe regulatory greenlight bolsters HUTCHMED's oncology portfolio and is expected to drive revenue growth for the company. Analysts view the approval as a positive development, highlighting the drug's potential in addressing a significant unmet medical need in the treatment of metastatic colorectal cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}